Akèy › Limfom zòn marenal
Etid klinik pou Limfom zòn marenal ap rekrite nan Etazini
55 etid pou Limfom zòn marenal ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Durham, NC12 etid
- New York City, NY11 etid
- Baldwin Park, CA9 etid
- Seattle, WA9 etid
- Boston, MA9 etid
- Milwaukee, WI9 etid
- Columbus, OH8 etid
- Edison, NJ8 etid
- Rochester, MN8 etid
- Houston, TX8 etid
- Denver, CO7 etid
- Miami, FL7 etid
- Jacksonville, FL6 etid
- St. Louis, MO6 etid
- Salt Lake City, UT6 etid
- Nashville, TN6 etid
- Cleveland, OH5 etid
- Dallas, TX5 etid
- Portland, OR5 etid
- Greenburgh, NY5 etid
- Queens, NY5 etid
- Atlanta, GA5 etid
- Chicago, IL5 etid
- Washington, DC5 etid
- Staten Island, NY4 etid
- Minneapolis, MN4 etid
- New Rochelle, NY4 etid
- Philadelphia, PA4 etid
- Buffalo, NY4 etid
- Tampa, FL4 etid
- Los Angeles, CA4 etid
- Cincinnati, OH4 etid
- Ann Arbor, MI3 etid
- Richmond, VA3 etid
- East Norwalk, CT3 etid
- San Francisco, CA3 etid
- Cedar Rapids, IA3 etid
- New Haven, CT3 etid
- Providence, RI3 etid
- Mountain View, CA3 etid
Pa eta
- Arizona5 etid
- Colorado8 etid
- Connecticut4 etid
- Florid15 etid
- Georgia6 etid
- Illinois6 etid
- Iowa4 etid
- Kalifòni18 etid
- Kansas3 etid
- Maryland6 etid
- Massachusetts12 etid
- Michigan5 etid
- Minnesota12 etid
- Missouri6 etid
- New Jersey9 etid
- New York16 etid
- North Carolina14 etid
- Ohio13 etid
- Oregon5 etid
- Pennsylvania5 etid
- Rhode Island3 etid
- Tennessee7 etid
- Texas12 etid
- Utah6 etid
- Virginia4 etid
- Washington10 etid
- Wisconsin10 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07231952Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07583810A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06350318Epco, Zanu, Ritux for R/R FL or MZL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05296070Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07225439A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04792502A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06149286HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06792825AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 a 81 · Tout sèks · Mizajou Aug 6, 2026 · NCT05990465A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06860880Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06905509Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.